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Abstract
Background: Primary malignant melanoma of the oesophagus (PMME) is an uncommon tumor.
PMME has an aggressive biological behavior, similar to melanomas developed elsewhere in the
body. Most patients die from distant metastases, and the overall 5 year survival rate is
approximately 4%.
Case presentation: We report a rare case of a solitary pulmonary metastasis found 5 years after
curative resection of primary esophageal melanoma. No other sites of metastatic disease were
identified. Video-assisted lung wedge resection of the lung nodule was carried out successfully.
Conclusion: This supports the concept that patients with primary melanoma of the oesophagus
treated should be carefully followed up.
Background
Primary melanoma of the oesophagus (PMME) is an
uncommon tumor with an incidence of 0.1% of esopha-
geal cancer and represents about 0.5% of noncutaneous
melanomas [1]. Firstly Baur reported a case in 1906 [2].
PMME was not widely accepted until de la Pava in 1963
demostrated the presence of melanocytes in normal
oesophageal mucosa in 4 of 100 normal esophagus at
autopsy examination. Tateshi reported an incidence of 8%
for the presence of melanocytes in the stratum basale of
normal esophagi of Japanese subjects [4]. Although the
presence of normal melanocytes in the esophagus has
been largely demonstrated, their origin is still debatable
[3]. Suzuki in a large study on surgical and autopsied spec-
imens reported a 0.1% and 0.14% incidence respectively
[5]. Two-hundreds cases are described in literature.
Almost 90% of PMME are located in the lower third of the
esophagus and melanosis seems to be a predisposing fac-
tor since it as been found in almost 25% of the patients
suffering for PMME [6]. Diagnosis is made by exclusion
criteria with no other primary cutaneous, ocular, mucosal
lesion detected. Histologically, the tumor is considered as
primary when it presents with a characteristic structure of
melanoma and contains pigment (melanin), neighboring
melanosis or melanocytic dysplasia is generally required
to distinguish it from metastatic disease, the tumor is
often polypoid and arise in an area of junctional changes
in the squamous epithelium [7]. Histopathological exam-
ination is usually mandatory to reach a definitive diagno-
sis since symptoms are not different from those of other
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poor survival, also when resected at an early stage. In fact
the tumor has an aggressive biological behavior, similar to
melanomas occurred elsewhere in the body. Most patients
die from distant metastases, and the 5 year survival rate is
approximately 4%. At the time of presentation, 40% of
patients have already metastatized, primarily to regional
lymph nodes, liver, lung, or bones [8]. Although pulmo-
nary metastasis from melanoma is not uncommon, the
case we report of a solitary pulmonary metastasis found 5
years after curative resection of the primary esophageal
tumor is extremely unusual [9,10]. A review of recent lit-
erature is also presented.
Case presentation
A 62-year-old caucasian woman, who had undergone cur-
ative resection of primary melanoma of the oesophagus 5
years earlier without adjuvant chemo-radiotherapy [9,10],
was referred to our hospital for a solitary pulmonary nod-
ule (13 × 10 mm) in the left upper lobe (LUL) detected
during routine follow-up chest X-ray examination. Tho-
racic computed tomography (CT) showed a well delim-
ited round tumor, about 13 mm in diameter located in the
LUL, with no mediastinal lymph-nodes enlargement (Fig-
ure 1); brain and abdominal CT performed for staging did
not find distant metasteses. Staging was then compleated
with flexible endoscopy (the remnant esophagus, stom-
ach and duodenum were normal), immunoscintigraphy
with 99 mTc-labeled melanoma monoclonal, bone scan
and broncoscopy which resulted all negative. Laboratory
tests were unremarcable. Video-assisted lung wedge resec-
tion of the pulmonary nodule was carried out success-
fully. A definitive pathological diagnosis was achieved:
the macroscopic examination of the surgical specimen
confirmed the CT findings. The final histology confirmed
proliferation of small spindle-shaped or stellate cells
arranged in a spiral or fascicular structure, the tumor cells
were intesively positive for immuno-reaction, using
HMB45 anti-melanoma antibodies (Figure 2, 3). These
findings were compatible with the diagnosis of metastases
of primary esophageal melanoma. The patient had an
uneventful postoperative course and is still well without
any evidence of further recurrence 6 months after surgery.
This is a rare case of solitary lung metastasis appearing 5
years after eradication of primary esophageal melanoma.
Discussion
Several explanations have been postulated for delayed
metastasis of differentiated tumors. Alexander presented
an intriguing pathogenic hypothesis proposing that clus-
ters of dividing cells lead to an equilibrium between cell
death and proliferation, or that the tumor cells remain in
a state of rest for long periods without losing their viabil-
ity before renewed tumor growth is induced by the
somatic transformation of the cancer cells [11]. We report
a rare case of a solitary pulmonary metastasis found 5
years after curative resection of primary esophageal
melanoma. Radical surgical resection with en bloc lym-
phadenectomy is the treatment of choice of primary
melanoma of the oesophagus, with a five year survival of
4.25% [8]. Although laser, radiotherapy, chemotherapy,
immunotherapy have not proven to be beneficial, they
may play a palliative role if surgery is not applicable for
advanced stages or poor functional status [12]. Of the
approximately 200 cases that have been reported to date,
only about 30% of the patients survived more than 1 year
after the initial diagnosis [8]. The aggressive biological
behavior of this disease, the advanced stage at the time of
Histology: section through pulmonary tissue showing meta-static melanoma (hematoxylin and eosin x40 and x100)Figure 2
Histology: section through pulmonary tissue showing meta-
static melanoma (hematoxylin and eosin x40 and x100).
Computed tomography: well delimited pulmonary nodule of 13 m in diamete  of the LULFigure 1
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poor prognosis. PMME is a very aggressive tumor and
esophagogastroduodenoscopy, endoscopic ultrasonogra-
phy and CT scan are required to complete the preoperative
staging. Chalkiadakis demonstrated that distant metas-
tases are present in 78% of the patients suffering from
PMME [13]. The most common site of metastases is the
liver (31%), followed by mediastinum (29%), lung
(17%), brain (13%) and other intra-abdominal organs.
Detection rate of metastatic disease identification using
immunoscintigraphy with 99 mTc-labeled melanoma
monoclonal AB is 95% for bone lesions, 91% for liver,
78% for lymph node metastases, 62% for brain, 62% for
spleen and 58% for lung [14,15]. This technique cannot
identify deposits of 1 cm or less in size [14,15]. Although
it has been demonstrated that radical resection increases
the survival compared to local treatment, 5-year survival is
less than 5%, mainly due to the advanced state of the dis-
ease at the time of diagnosis [16]. Various drugs, alone or
in combination, including vinblastine, bleomycin,
lomustine, vincristine and recently recombinant inter-
feron-alpha and interleukin-2, have been used with vary-
ing results as palliative treatment of cutaneous melanoma
[17-20]. Combination of cisplatin, carmustine, dacar-
bazine and tamoxifen have also been studied with prom-
ising results in cutaneous melanoma patients with
advanced disease [21]. Several investigators have sup-
ported the above findings and the role of tamoxifene as
drugs modulator [22-24]. Nevertherless, none of these
regimens have been used in esophageal melanomas
which is considered to be a radioresistant tumor, and
chemotherapy, external beam and intracavitary radiother-
apy may only have a palliative role [25]. At the time of
diagnosis, clinically, surgically or pathologically detecta-
ble metastases were present in 40.9% of patients. The
overall survival is 9.8 months with five year survival rate
of 1.69%. Only 33% of patients survive for more than 1
year after diagnosis. Deaths are disease-related in 75–85%
of cases [8].
Although the reason for the delayed presentation of the
metastatic lesion remains unclear, the case report we
described demonstrates that patients with primary
melanoma of the oesophagus surgically treated should be
carefully followed up.
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